Sibylla Biotech Enters a Strategic Drug Discovery Collaboration with Ono Pharmaceutical in Central Nervous System Disorders [Yahoo! Finance]
ONO PHARM CO UNSP/ADR (OPHLY)
NASDAQ:AMEX Investor Relations:
ono.co.jp/eng/investor/index.html
Company Research
Source: Yahoo! Finance
will access Sibylla's cutting-edge Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology to identify and develop candidates for multiple therapeutic targets in the field of Central Nervous System (CNS) disorders. Under the terms of the collaboration, Sibylla is entitled to a total deal value in the three-digit millions of U.S. dollars, including upfront payment, research, development and sales milestones, and royalties on sales. Further financial details on the collaboration have not been disclosed. Sibylla Biotech utilizes its PPI-FIT technology to design Folding Interfering Degraders (FIDs). FIDs are small molecules that induce the degradation of a target protein by interfering with its folding pathway. The technology targets specific proteins, particularly those considered "undruggable" due to the absence of suitable pockets in their native state. Ono Pharmaceutical plans to harness this technology to address some of the most challenging asp
Show less
Read more
Impact Snapshot
Event Time:
OPHLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPHLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPHLY alerts
High impacting ONO PHARM CO UNSP/ADR news events
Weekly update
A roundup of the hottest topics
OPHLY
News
- XCOPRI® (cenobamate tablets) CV Receives FDA Approval for Alternate Methods of Administration That Include Crushed Tablet in Liquid Suspension Taken Orally or Through a Nasogastric Tube [Yahoo! Finance]Yahoo! Finance
- SK Life Science Announces Data Presentations for XCOPRI® (cenobamate tablets) CV at the 2024 American Academy of Neurology Annual Meeting [Yahoo! Finance]Yahoo! Finance
- ONO PHARMA Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL [Yahoo! Finance]Yahoo! Finance
- ONO Enters into a University-Wide, Research Alliance Agreement with Harvard University [Yahoo! Finance]Yahoo! Finance
- Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets [Yahoo! Finance]Yahoo! Finance